Gyroscope Therapeutics Appoints Jessica Stitt as Chief Financial Officer
Published on 1 Mar 2021
2020 clinical trials database report confirms the UK as an internationally attractive clinical space for the development of cell and gene therapies
Published on 23 Feb 2021
Stevenage Bioscience Catalyst launches accelerator programme for biotech start-ups
Published on 22 Feb 2021
Michael J. Parini joins from Vertex as President and Chief Operating Officer complementing recent General Counsel and Investor Relations appointments Chief Financial Officer Brian M. Silver leaving Freeline to pursue a new opportunity
Published on 22 Feb 2021
Cell and Gene Therapy Catapult appoints Dr. Ian Campbell as Innovate UK nominated non-executive Director
Published on 22 Feb 2021
Gyroscope Therapeutics Announces Positive Interim Data from Phase I/II FOCUS Trial of Investigational Gene Therapy GT005
Published on 15 Feb 2021
Rentschler Biopharma to build new cell and gene therapy capabilities in the UK
Published on 15 Feb 2021
Stevenage Bioscience Catalyst Welcomes New Occupier Galecto, Inc.
Published on 15 Feb 2021
LifeArc provides £5 million funding to increase understanding of the role of genetic risk factors in patient response to COVID-19
Published on 15 Feb 2021

Peptinnovate announces change of name to Immune Regulation, strengthening of the Board and successful fundraise

Read the article
The appointment of these three experienced industry executives will bring valuable insight and resource to our Board and executive team. With their skills in immunology, clinical therapeutic development and strategy we have the expertise to advance our clinical programmes and look forward to the next stage of our progress.
Prof. Clive Page
Chairman of Immune Regulation
Freeline Therapeutics Updates Clinical Development Plan for its FLT180a Hemophilia B Program
Published on 9 Feb 2021
LifeArc working with the Crohn’s & Colitis Foundation to develop a prognostic test for Crohn’s disease in children
Published on 26 Jan 2021
CGT Catapult’s third annual clinical adoption workshop offers recommendations for advancing institutional readiness across the NHS to accelerate the routine adoption of cell and gene therapies
Published on 26 Jan 2021
Metrion Biosciences and LifeArc further extend neuroscience-focused ion channel drug discovery collaboration
Published on 19 Jan 2021
Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseases
Published on 19 Jan 2021
Stevenage Bioscience Catalyst announces James Latham as Development and Leasing Director
Published on 12 Jan 2021
Hertfordshire LEP to part-fund state-of-the-art cell and gene therapy training centre to strengthen the sector’s skills pipeline
Published on 5 Jan 2021
Dr Sally Ann Forsyth CEO Stevenage Bioscience Catalyst Awarded OBE for Services to Business and Science
Published on 30 Dec 2020
Immune Regulation appoints New Chairman and builds out Senior Management Team with standout industry professionals in the US
Published on 22 Dec 2020
LifeArc co-leads £6 million funding in DJS Antibodies
Published on 22 Dec 2020
CGT Catapult has won the 2020 Pharmaceutical Industry Network Group (PING) Innovation Award, hosted by VWV
Published on 15 Dec 2020
UK set to take advanced therapies and vaccine manufacturing industry to the next level: the Advanced Therapy Skills Training Network launches today – driven by industry and coordinated by the Cell and Gene Therapy Catapult
Published on 4 Dec 2020

Copyright © 2021 Stevenage Bioscience Catalyst

Designed and built by Onespacemedia

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.